DIRS.INFO The most relevant business & tech news

☆ Earnings playbook: How to trade some of the biggest reports this week, including Apple
▼ + stars: | 2023-07-31 | by ( Fred Imbert | ) www.cnbc.com time to read: +8 min

This quarter: Analysts polled by FactSet expect Merck to post a loss for the first quarter. Starbucks is set to report earnings after the bell, with management slated to hold a call at 5 p.m. This quarter: Analysts polled by FactSet expect double-digit earnings growth quarter over quarter. What history shows: Bespoke data shows Amazon earnings exceed earnings expectations 62% of the time. Apple is set to report earnings after the close, followed by a call at 5 p.m.

Persons: Goldman Sachs, Annika Kim Constantino, Merck, Merck's, Joe Biden's, SBUX, Bank of America's Sara Senatore, Senatore, Albert Bourla, —, They're, AMZN, FactSet, Annie Palmer, Morgan Stanley, Erik Woodring, — CNBC's Michael Bloom Organizations: Netflix, Merck, Apple, FactSet, CNBC, Prometheus Biosciences, Investment, Bank of America's, Pfizer, Management, Amazon Web Services, IDC Locations: China, 2Q23, New York, Carolina, Friday's

☆ NIH to test Pfizer’s Paxlovid, other treatments as potential long Covid therapies
▼ + stars: | 2023-07-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

The National Institutes of Health said Monday it launched mid-stage clinical trials to test at least four treatments, including Pfizer 's antiviral Covid-19 pill Paxlovid, as potential therapies for long Covid. But the lack of a specific long Covid treatment pushes some patients to seek unproven – and potentially dangerous – remedies for the condition. "NIH is committed to a highly coordinated and scientifically rigorous approach to find treatments that will provide relief for the millions of people living with long COVID." The NIH will test the safety and effectiveness of the treatments – which include both drugs and medical devices – in groups of 100 to 300 patients with long Covid symptoms. The first part of the phase two trial will test a longer dosing regimen of Paxlovid to see if it improves long Covid symptoms.

Persons: Lawrence Tabak Organizations: National Institutes of Health, Pfizer, Health, NIH

☆ New Covid vaccines are coming to the U.S. this fall, but uptake may be low — Here’s why
▼ + stars: | 2023-07-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +7 min

Regardless of that shift, experts say vaccine uptake may not look much different from that of the bivalent boosters. Pandemic fatigue, confusionFatigue over the pandemic and the general belief that Covid is "over" could potentially hinder the uptake of new shots this fall, experts said. Ipsos and Axios released a survey with similar findings in May, the same month the U.S. ended the national Covid public health emergency amid a downward trend in cases, hospitalizations and deaths. "That contrasts with what we've seen in the past where there are different vaccines, different timing, different age groups and something new to consider every few months." Advisors to the FDA have raised concerns about shifting to yearly Covid vaccines, noting that it's unclear if the virus is seasonal like the flu.

Persons: Antonio Perez, Axios, isn't, Dr, Kartik Cherabuddi, Brad Pollock, Pollock, they're, Ashley McGee, Justin Sullivan, CDC hasn't, Covid, KFF's Kates, Michael Nagle, Kates, we've Organizations: Chicago CVS, Tribune, Service, Getty Images Pfizer, Moderna, Pfizer, Gallup, University of Florida, CNBC, UC Davis Health's, Safeway, CDC, Food and Drug Administration, Health, Human Services Department, FDA, Xinhua News Agency, Getty Locations: Chicago, U.S, San Rafael , California, New York, United States

☆ Johnson & Johnson effort to resolve talc cancer lawsuits in bankruptcy fails a second time
▼ + stars: | 2023-07-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

In this photo illustration, a container of Johnson and Johnson baby powder is displayed on April 05, 2023 in San Anselmo, California. A federal bankruptcy judge on Friday rejected Johnson & Johnson 's second attempt to resolve tens of thousands of lawsuits alleging the company's talc baby powder and other talc-based products caused cancer. J&J in 2021 offloaded those talc liabilities into a new subsidiary, LTL Management, and immediately filed for Chapter 11 bankruptcy protections. "LTL commenced its bankruptcy case in good faith and in strict compliance with the Bankruptcy Code," J&J said in a statement. J&J contends that research and clinical evidence demonstrates that its talc products remain safe.

Persons: Johnson, Michael Kaplan, LTL, J's, J, Erik Haas Organizations: LTL Management Locations: San Anselmo , California, Trenton , New Jersey

☆ Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials
▼ + stars: | 2023-07-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Mike Blake | ReutersTrial resultsOne trial, called Surmount-4, evaluated more than 600 people over two periods. Patients took tirzepatide for 36 weeks and achieved 21.1% weight loss on average. Overall, patients who stayed on the drug lost 26% of their weight on average after 88 weeks. The experimental obesity drug helped patients lose around 24% of their weight, setting a new bar for weight loss in mid-stage clinical trials. A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023.

Persons: Eli Lilly, Mike Blake, tirzepatide, Dr, Jeff Emmick, Eli Lilly's, Eli Lilly's tirzepatide, Jim Vondruska Organizations: Wegovy Locations: San Diego , California, Chicago , Illinois

☆ UK investigates weight loss, diabetes drugs like Wegovy and Ozempic for suicide risks
▼ + stars: | 2023-07-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. U.K. health authorities on Wednesday said they are reviewing obesity and diabetes drugs like Novo Nordisk 's Wegovy and Ozempic after some patients who took the treatments reported thoughts of suicide or self-harm. The MHRA said the review includes all obesity and diabetes drugs available in the U.K. Aside from Ozempic and Wegovy, it includes Novo Nordisk's other weight loss drug Saxenda. Other diabetes drugs like AstraZeneca 's Bydureon, Eli Lilly 's Trulicity and Sanofi 's Lyxumia are also included in the probe. Novo Nordisk said in a statement that it received a review request from the MHRA on Monday.

Persons: MHRA, Eli Lilly, Sanofi Organizations: Novo Nordisk, Nordisk, Medicines, Healthcare, Agency, CNBC, European Union, AstraZeneca, Reuters Locations: Danish, U.S, Novo

☆ GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales
▼ + stars: | 2023-07-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

GlaxoSmithKline CEO Emma Walmsley on Wednesday said she expects uptake for the company's new RSV vaccine to start off slower than it did for its blockbuster shingles shot. Last month, GSK's RSV shot became the first to win approval in the U.S. and European Union for the treatment of adults 60 and above. The company has not provided estimates for how much revenue the RSV shot will rake in this year following its launch. GSK's vaccine against shingles, a viral infection that causes a painful rash, is the company's top-selling drug. Investors are hoping that Shingrix and GSK's RSV shot will help offset patent expirations for some of the company's blockbuster HIV drugs in a few years.

Persons: Emma Walmsley, Walmsley Organizations: GSK, Union, U.S, European Union, Investors Locations: London, U.S, Japan, Canada

☆ Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch
▼ + stars: | 2023-07-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Biogen on Tuesday said it expects to cut approximately 1,000 jobs, or about 11% of its workforce, to save costs as the biotech company prepares to launch its newly approved Alzheimer's drug Leqembi. It's the latest round of layoffs after Biogen slashed nearly 900 jobs last year. The larger plan is expected to generate approximately $1 billion in gross operating expense savings by 2025, according to Biogen. About $300 million of those savings will be reinvested into product launches and R&D programs. "There's a need, obviously, to have a strong investment in our new product launches.

Persons: Chris Viehbacher, Wells, Mohit Bansal

☆ Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer
▼ + stars: | 2023-07-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson on Monday said it plans to reduce by at least 80% its stake in Kenvue, the consumer health business it spun out as an independent company earlier this year, via a stock exchange offer. J&J owns 89.6% of Kenvue's common stock, which amounts to more than 1.72 billion shares. The exchange offer, also known as a split-off, will allow J&J shareholders to swap all or a portion of their shares for Kenvue's common stock at a 7% discount. J&J first announced its intent to launch an exchange offer in its second-quarter earnings report on Thursday, but the company provided few details on the plan. When asked about J&J's planned exchange offer on Thursday, Kenvue CEO Thibaut Mongon told CNBC's "Squawk on the Street" that the company is "pleased with the way that the IPO has been received by shareholders."

Persons: Johnson, J, Joaquin Duato, Duato, Kenvue, J's, Thibaut Mongon, CNBC's Organizations: J Locations: Kenvue

☆ Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas
▼ + stars: | 2023-07-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Most consumers have pulled back on spending as inflation squeezes their wallets, but they have not stopped paying up for brand-name health and personal care products, Kenvue CEO Thibaut Mongon said. Kenvue also noted that "private label" penetration in the consumer health product market was stable for the quarter. Those spending trends could bode well not only for Kenvue, but also for other companies in the consumer health, beauty and beverage spaces that may not see consumers trade down to cheaper products as often despite stubbornly high prices. RBC Capital analyst Nik Modi expressed confidence in Kenvue's ability to "maintain its momentum," highlighting consumer trust in the company's brands and health and personal care products overall. Meanwhile, Kenvue has gained market share, and could potentially continue to do so despite the broader environment, he noted.

Persons: Thibaut Mongon, Johnson, Mongon, Kenvue, bode, we've, Nik Modi, Modi Organizations: Kenvue Inc, New York Stock Exchange, CNBC, Johnson, J, RBC Capital Locations: Kenvue

☆ Pfizer says no major tornado damage to drug manufacturing areas of North Carolina facility
▼ + stars: | 2023-07-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

In this aerial image, damage is seen to a Pfizer pharmaceutical factory after a tornado hit the facility two days earlier, on July 21, 2023 in Rocky Mount, North Carolina. Pfize r on Friday said there does not appear to be major damage to the drug manufacturing areas of its plant in Rocky Mount, North Carolina, after a tornado hit the facility two days earlier. The North Carolina plant is closed while Pfizer and both local and federal authorities further evaluate the damage. It's one of 10 Pfizer manufacturing sites in the country. Pfizer also noted that it is working closely with Food and Drug Administration Commissioner Robert Califf, North Carolina Gov.

Persons: it's, Robert Califf, Roy Cooper, Califf Organizations: Pfizer, Food and Drug, North Carolina Gov, FDA Locations: Rocky Mount, North Carolina, U.S, North

☆ Johnson & Johnson investors can soon swap their shares for Kenvue stock — here's what you need to know
▼ + stars: | 2023-07-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson on Thursday said its shareholders will soon be able to swap their shares for stock of Kenvue , which spun out as an independent consumer health company just two months ago. That process, also known as a split-off, will allow J&J shareholders to exchange all or a portion of their shares for Kenvue's common stock. Kenvue shares fell following the announcement Thursday, even though the company beat earnings and revenue estimates in its first quarterly report since its IPO. Previously, J&J did not disclose whether it would divest its Kenvue shares through a split-off or a spinoff. The latter would involve distributing Kenvue stock to existing J&J shareholders rather than giving them the option to exchange.

Persons: Thibaut Mongon, Paul Ruh, Johnson, J, Joseph Wolk, Wolk, J's, CNBC's, Kenvue, Goldman Sachs, JPMorgan Chase Organizations: Kenvue Inc, New York Stock Exchange, JPMorgan Locations: New York City, U.S

☆ Kenvue earnings top estimates in J&J spinoff's first quarterly report since IPO
▼ + stars: | 2023-07-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Kenvue reported second-quarter revenue and adjusted earnings that topped expectations Thursday in the consumer health company's first quarterly report since it spun out from Johnson & Johnson two months ago. But J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the spinoff's business for now. Excluding certain items, the company's adjusted earnings were 32 cents a share. The company's full-year adjusted earnings outlook is $1.26 to $1.31 per share. The company reported sales growth across its three business divisions in the second quarter.

Persons: Kenvue, Johnson, Kenvue's, Thibaut Mongon, headwinds, Mongon Organizations: Johnson, Refinitiv, Deutsche Bank Global Consumer Conference Locations: Kenvue, Canada

☆ Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge
▼ + stars: | 2023-07-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations, and lifted its full-year guidance as sales from the company's medtech business jumped. That compares with a net income of $4.8 billion, or $1.80 per share, for the same period a year ago. Excluding certain items, adjusted earnings per share were $2.80 for the period. J&J is now forecasting full-year sales of $98.80 billion to $99.80 billion, about $1 billion higher than the guidance provided in April. The company raised its 2023 adjusted earnings outlook to $10.70 to $10.80 per share, from a previous forecast of $10.60 to $10.70 per share.

Persons: Johnson Organizations: UnitedHealth, Elevance, Refinitiv

☆ Pfizer Group B strep vaccine for infants returns encouraging mid-stage trial results
▼ + stars: | 2023-07-19 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer on Wednesday said its experimental vaccine targeting the potentially deadly bacterial disease Group B Streptococcus returned strong mid-stage clinical trial results, a promising step as the drug inches toward potential approval. Pfizer is among several drugmakers racing to develop the world's first shot targeting Group B strep disease, which is linked to nearly 150,000 infant deaths worldwide each year, especially in lower-income countries. Pfizer's single-dose shot generated antibodies that may provide infants with meaningful protection against the disease, according to the data released Wednesday from a phase two clinical trial. Pfizer's encouraging phase two trial results provide hope that maternal vaccination against the disease, also known as GBS, could help prevent thousands of cases in babies. The results will also help the company plan its phase three clinical trials on the shot, which are typically required before the FDA approves a drug.

Persons: Streptococcus, Melinda Gates Organizations: Pfizer, Drug Administration, FDA, Melinda Gates Foundation

☆ Johnson & Johnson sues Biden administration over Medicare drug price negotiations
▼ + stars: | 2023-07-18 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Johnson & Johnson on Tuesday sued the Biden administration over Medicare's new powers to slash drug prices, making it the third pharmaceutical company to challenge the controversial provision of the Inflation Reduction Act. The lawsuit filed in federal district court in New Jersey argues the Medicare negotiations violate the First and Fifth Amendments of the U.S. Constitution. J&J also argues that the new provision forces the company to agree that the federal government is negotiating fair drug prices. The company believes the provision doesn't involve true negotiations since the government "unilaterally dictates" drug prices. HHS said in a statement it will "vigorously defend the President's drug price negotiation law, which is already helping to lower health care costs for seniors and people with disabilities."

Persons: Johnson, drugmakers Merck, Joe Biden's, J, Xavier Becerra Organizations: Biden, U.S . Constitution, Bristol Myers Squibb, U.S . Chamber of Commerce, PhRMA, . Health, Human Services Department, Medicare, Services, HHS Locations: New Jersey, U.S ., United States, Xarelto

☆ Novartis stock jumps after drugmaker raises full-year guidance, launches $15 billion buyback
▼ + stars: | 2023-07-18 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Novartis shares jumped on Tuesday after the Swiss drugmaker raised its full-year guidance on strong drug sales and announced a $15 billion share buyback. Novartis expects sales to rise by a high-single-digit percentage in 2023, an increase from a previous expectation of mid-single-digit growth. Novartis reported total revenue of $13.62 billion for the quarter, up around 7% from $12.78 billion the same period a year ago. The company's innovative medicines business, which develops patented medicines, raked in sales of $11.24 billion for the quarter. The company's generic medicines division, Sandoz, posted sales of $2.38 billion, up 5% from a year ago.

Persons: Sandoz, Roche Organizations: Novartis, Refinitiv, Sandoz Locations: Swiss, U.S

☆ Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
▼ + stars: | 2023-07-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Eli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer's treatment, donanemab, and expects the agency to make a decision by the end of the year. "The earlier you begin to use the drug perhaps the more slowing that can be," Eli Lilly CEO David Ricks said in an interview on CNBC's "Squawk on the Street" on Monday. Eli Lilly is among the pharmaceutical companies racing to market new treatments for the disease after Eisai and Biogen's drug Leqembi won FDA approval this month. The agency's signoff on Leqembi was a milestone in the treatment of Alzheimer's, even though the drug and donanemab aren't cures. An FDA approval of Eli Lilly's donanemab would expand the treatment options for the more than 6 million Americans of all ages who have Alzheimer's, the fifth-leading cause of death for adults over 65.

Persons: Eli Lilly, Monday, David Ricks, Leqembi, Eli Lilly's donanemab, Ricks Organizations: U.S, Food, Drug, Medicare, Services, CNBC Locations: Leqembi

☆ UnitedHealth stock jumps after earnings top estimates despite rising medical costs
▼ + stars: | 2023-07-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

UnitedHealth Group' s stock price jumped Friday after the health-care conglomerate reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations despite rising medical costs. UnitedHealth Group is the biggest health-care company in the U.S. by market cap and revenue, and is even bigger than the nation's largest banks. Given its size, UnitedHealth Group is considered a bellwether for the broader health insurance sector. UnitedHealth Care said that was driven by the previously noted uptick in elective surgeries and outpatient care activity, primarily among seniors. But UnitedHealth Group executives indicated that the trend may be reversing.

Persons: UnitedHealth, –, John Rex, Rex, Goldman Sachs Organizations: UnitedHealth, Refinitiv, Healthcare, Analysts, Goldman, Rex . Insurance Locations: Minnesota, U.S

☆ Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion
▼ + stars: | 2023-07-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Eli Lilly on Friday said it will acquire Versanis, a privately held obesity drug maker, for up to $1.93 billion to boost the pharmaceutical giant's weight loss treatment portfolio. Eli Lilly agreed to pay Versanis shareholders in cash, which will consist of an upfront payment and potentially subsequent payments if Versanis achieves certain "development and sales milestones." Oakland, California-based Versanis, which was founded in 2021 by biotech investment firm Aditum Bio, has one experimental drug for obesity and potentially other conditions. Analysts project that the global weight loss drug market could be worth $100 billion by around 2030. Versanis' drug, bimagrumab, binds directly to certain cells in the body to reduce fat mass.

Persons: Eli Lilly, Versanis, Aditum, Eli Lilly's Organizations: Novo Nordisk, Novo Nordisk's Wegovy Locations: Oakland , California, Ozempic, U.S, Indianapolis

☆ Uninsured Americans pay high costs for an insulin Eli Lilly vowed to price at $25, Sen. Warren says
▼ + stars: | 2023-07-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Uninsured Americans pay nearly $98 on average for a vial of Eli Lilly 's generic insulin, even after the company pledged to cut the product's list price to $25 per vial, according to a report released Thursday by Sen. Elizabeth Warren. Eli Lilly earlier this year vowed to slash the list price of its generic insulin, Lispro, from $82.42 per vial starting on May 1. The survey found that a third of pharmacies charged uninsured patients $164 or more for a vial of Eli Lilly's Lispro. Eli Lilly did not immediately respond to a request for comment on the survey.

Persons: Eli Lilly, Sen, Elizabeth Warren, Eli Lilly's, Eli Lilly's Lispro, Warren, Joe Biden's Organizations: Company, Medicare Locations: Branchburg , New Jersey, Indianapolis, Massachusetts, U.S

☆ Biden administration to provide free Covid vaccines to uninsured Americans this fall through end of 2024
▼ + stars: | 2023-07-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Biden administration on Thursday announced a program to provide free Covid vaccines to uninsured Americans through December 2024 after the federal government's supply of shots runs out this fall. Those free shots, which the government is purchasing at a discount, will be available to the uninsured at pharmacies and 64 state and local health departments. There are between 25 to 30 million uninsured adults in the United States and other Americans whose insurance will not cover free Covid products this fall, according to the federal Centers for Disease Control and Prevention. In the fall, the companies will begin selling shots directly to health providers, and the government's supply is expected to run out. Earlier this year, the World Health Organization declared an end to the global Covid public health emergency earlier this year.

Persons: Biden Organizations: Pfizer, BioNTech, Peabody Institute Library, The, Human Services Department, for Disease Control, Moderna, World Health Organization, HHS Locations: Peabody , Massachusetts, United States, Novavax

☆ Biden administration asks Pfizer, Moderna and Novavax for 'reasonable' prices on updated Covid vaccines
▼ + stars: | 2023-07-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A nurse prepares doses of the Pfizer vaccine on Dec. 30, 2021, during a COVID-19 vaccination event at Josephine's Southern Cooking in Chatham, Illinois. The Biden administration on Thursday urged Pfizer , Moderna and Novavax to price their updated Covid vaccines at a "reasonable" rate when they roll them out in the U.S. this fall. A Moderna spokesperson reiterated the company's previous remarks about being ready in time for the fall with ample vaccine supply. Federal and corporate programs are planning to help shoulder the out-of-pocket costs of updated shots this fall for uninsured Americans. Pfizer and Moderna also intend to launch patient assistance programs for their Covid shots.

Persons: Biden Organizations: Pfizer, Moderna, Department of Health, Human Services, CNBC, U.S, HHS, Centers, Medicare, Medicaid Services, Food and Drug Administration, for Disease Control, Federal Locations: Chatham , Illinois, Novavax, U.S

☆ FDA approves Opill, the first over-the-counter birth control pill
▼ + stars: | 2023-07-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

HRA Pharma expects a final decision by the FDA this summer on its application for nonprescription sales of Opill, which is generically called norgestrel. The Food and Drug Administration on Thursday approved the first over-the-counter birth control pill, a landmark decision that will allow more women and girls in the U.S. to prevent unintended pregnancies without a prescription. The daily pill, called Opill, was first approved by the FDA as a prescription in 1973. Medical organizations like the American College of Obstetricians and Gynecologists and women's health advocates have pushed for wider access. More than 50 members of Congress in March 2022 also called on FDA Commissioner Dr. Robert Califf to ensure the agency reviewed applications for over-the-counter birth control pills without delay.

Persons: Biden, Wade, –, Welgryn, Robert Califf, Patrizia Cavazzoni, Opill Organizations: HRA Pharma, FDA, Drug Administration, American College of Obstetricians, FDA's Center, Drug, Research Locations: U.S, Paris, Dublin

☆ FDA to review Schumer's concerns about YouTube stars' Prime Energy drink
▼ + stars: | 2023-07-12 | by ( Chelsey Cox | ) www.cnbc.com time to read: +2 min

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, August 29, 2020. WASHINGTON — The Food and Drug Administration will address concerns raised by Senate Majority Leader Chuck Schumer about a caffeinated energy drink popular among teens. An agency spokesperson said it "is reviewing the concerns" outlined in Schumer's letter to FDA Commissioner Dr. Robert Califf about the dangers of Prime Energy, a beverage founded by YouTube stars Logan Paul and KSI. Prime Energy is not intended for anyone under the age of 18, according to a company representative. Prime Energy boasts 200 mg of caffeine.

Persons: Chuck Schumer, Robert Califf, Logan Paul, KSI, Schumer, Paul, Annika Kim Constantino Organizations: Food and Drug Administration, FDA, WASHINGTON, Drug Administration, Energy, YouTube, Prime Energy, American Academy of Child, Psychiatry Locations: White Oak , Maryland

Search resuls for: "Constantino"

25 mentions found